U.S. medical technology shares fell Thursday after the Commerce Department launched an investigation into imports of medical devices, raising the possibility of future tariffs.
Market Impact
GE HealthCare, Becton Dickinson, Stryker, Insulet, Intuitive Surgical, and ResMed each dropped between 3% and 9%. Abbott slipped 1.6% and Medtronic fell 1.7%, pushing the S&P Health Care Equipment index down 1.6% for the day.
Reasons for Concern
Analysts said the probe could weigh on companies that rely on globally sourced supply chains. Medtech stocks have already faced a turbulent year due to supply chain disruptions, higher costs, and slowing international demand.
Investigation Details
Earlier this month, the Commerce Secretary launched a Section 232 investigation under the Trade Expansion Act of 1962. The review will determine whether imports of personal protective equipment, medical consumables, and devices threaten U.S. national security. Recommendations are expected within 270 days.
Industry Response
A GE HealthCare spokesperson said the company supports efforts to strengthen U.S. healthcare resilience and local manufacturing. J.P. Morgan analyst Robbie Marcus cautioned investors not to “hit the panic button,” noting the probe’s broad scope but uncertain outcome.
Global Ripple
Healthcare and industrial stocks in Europe also dipped, reflecting wider market unease over potential U.S. trade actions.
For more business news, tune in to Que Onda Magazine.